BioRestorative Therapies, Inc. Stock Other OTC
Equities
BRTX
US0906554086
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 60K | Sales 2025 * | 60K | Capitalization | 9.27M |
---|---|---|---|---|---|
Net income 2024 * | -17M | Net income 2025 * | -20M | EV / Sales 2024 * | 155 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 155 x |
P/E ratio 2024 * |
-0.64
x | P/E ratio 2025 * |
-0.65
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.2% |
Managers | Title | Age | Since |
---|---|---|---|
Lance Alstodt
CEO | Chief Executive Officer | 53 | 18-09-30 |
Robert Kristal
DFI | Director of Finance/CFO | - | 21-11-03 |
Compliance Officer | 55 | 15-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Williams
BRD | Director/Board Member | 51 | 21-10-28 |
David Rosa
BRD | Director/Board Member | 59 | 21-10-28 |
Francisco Silva
CTO | Chief Tech/Sci/R&D Officer | 49 | 11-04-12 |
1st Jan change | Capi. | |
---|---|---|
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |